IL6 and COVID-19: Meanwhile, we cannot ignore the limitation of the small sample size, and loss of information regarding biomarkers of cardiac damage, lung echography, and IL6 level in patients in the current study; therefore, further studies including larger sample size are needed to confirm the efficacy of CCBs in treating COVID-19 patients who have hypertension as the comorbidity.